All Insight, Analysis and Views

ViewPoints: Iovance reportedly attracting Big Pharma glances
Ref: ViewPoints Desk
Tags: ViewPointsIovance BiotherapeuticsMelanoma Clinical Research (R&D) Corporate Affairslifileucel
ViewPoints: Pfizer sets its stage for DMD gene therapy readouts
Ref: ViewPoints Desk
Tags: ViewPointsPfizer Sarepta Therapeutics Solid BiosciencesDuchenne Muscular Dystrophy Clinical Research (R&D) Regulatory AffairsPF-06939926 SRP-9001 SGT-001
ViewPoints: Moderna, Gilead lead coronavirus charge
Ref: ViewPoints Desk
Tags: ViewPointsGilead ModernaCOVID-19 Clinical Research (R&D) Corporate AffairsmRNA-1273 Remdesivir
ViewPoints: Vasculitis may be a momentum killer for Novartis’ Beovu
Ref: ViewPoints Desk
Tags: ViewPointsBayer Novartis Regeneron Roche FDAMarketing & Sales Medical AffairsBeovu Eylea Lucentis
Physician Views snap poll: Will safety concerns slow early adoption of Novartis' Beovu?
Ref: Physician Views Desk
Tags: Physician ViewsNovartis Regeneron RocheAMD Clinical Research (R&D) Medical AffairsBeovu
Physician Views snap poll: How will cardiologists utilise Esperion's newly approved Nexletol?
Ref: Physician Views Desk
Tags: Physician ViewsEsperionDyslipidemia Clinical Research (R&D) Medical AffairsNexletol
ViewPoints: NGM hauls in an FGF victory
Ref: ViewPoints Desk
Tags: ViewPointsNGM Biopharmaceuticals BMS Akero TherapeuticsNonalcoholic steatohepatitis Clinical Research (R&D)Aldafermin pegbelfermin AKR-001
ViewPoints: Esperion can initiate long-awaited payer discussions unencumbered
Ref: ViewPoints Desk
Tags: ViewPointsEsperion Amgen Sanofi Regeneron NovartisDyslipidemia FDAMarketing & Sales Medical Affairs Regulatory AffairsNexletol Repatha Praluent inclisiran Nexlizet
Physician Views snap poll results: AbbVie's Rinvoq looks well placed to take future share in psoriatic arthritis market
Ref: Physician Views Desk
Tags: Physician Views Poll ResultsAbbVieArthritis Psoriasis Clinical Research (R&D) Medical AffairsRinvoq
ViewPoints: Merck KGaA says study redesign reflects increased confidence in MS hopeful
Ref: ViewPoints Desk
Tags: ViewPointsMerck KGaA Sanofi RocheMultiple Sclerosis Clinical Research (R&D)Evobrutinib SAR442168 Ocrevus